Acquired Resistance to Therapy Network (ARTNet)

The Acquired Resistance to Therapy Network (ARTNet), of @theNCI focuses on mechanisms of acquired resistance to cancer therapies & disease recurrence and integrates those findings through team science. Learn more at nciartnet.org and t.ly/ZbxF3

Recent patents relating to bispecific antibody compositions and methods of use nature.com/articles/s4158… rdcu.be/fwItG

A fascinating episode and well worth your time! #ARTNetPodcast Episode 2: theartnetpodcast.riverside.com/e/resistance-b… In this episode, Dr. David Goodrich of @RoswellPark speaks with Dr. @VSandulache2025 of @bcmhouston about emerging research showing that many tumors may already be biologically primed to resist therapy before treatment even starts. Together, they explore how oxidative stress, metabolism, immune interactions, and environmental exposures shape tumor behavior, discuss the role of the NRF2 pathway in treatment resistance, and examine how these insights could lead to better biomarkers and more personalized treatment strategies for patients with head and neck cancer.

High-plasticity oncofetal cell states in early pre-metastatic colorectal cancer dlvr.it/TTYV79

📢 Save the date! Join @theNCI Office of Data Sharing (ODS) Join Fourth Annual Symposium, Data to Discovery: Leveraging Cancer Data in the "Real World," on Nov. 5-6, 2026 in Rockville, MD. Submit a poster or demo abstract by Sept. 1 (travel award eligibility deadline: Aug. 3). Help advance cancer research through data sharing! events.cancer.gov/ods/annualdata… #CancerResearch #DataSharing #FAIRData

Register now for the upcoming NCI Office of Data Sharing Seminar Series on July 29, 2026! Join Dr. Julian Hong of @UCSF as he presents "Generalizable Multimodal AI Approaches to Advance Cancer Care Delivery." Register here: events.cancer.gov/ods/webinar/up…

📢 Registration deadline extended! Join the 2026 #NCIDataJamboree (Nov. 16–18) to collaborate with researchers, trainees, patients, advocates, and citizen scientists using public cancer datasets to advance cancer research. Submit your project and register by July 27, 2026. events.cancer.gov/nci/datajambor… #CancerResearch #OpenScience #DataScience

Whole-genome doubling drives immune evasion by silencing antigen presentation dlvr.it/TTWTXg

Clonal lineage tracing of innate immune cells in human cancer dlvr.it/TTXYR2

At today's Functional Screens and Assays #ARTNetWG meeting, Dr. Erik Knudsen of @RoswellPark presented an update on the collaborative drug screening project that Roswell Park is conducting with other ARTNet research centers.

At today's #ARTNetSCMeeting, co-chair Dr. Alan Hutson @Amherst73 of @RoswellPark provided updates on ARTNet's recent activities and upcoming initiatives. Associate member Dr. Jennifer Wargo @JenWargoMD of @UTMDAnderson shared exciting advances on how the microbiome shapes cancer development, immune responses, and immunotherapy outcomes. Her presentation highlighted emerging strategies to modulate the microbiome through diet, probiotics, and life style, opening new possibilities for cancer prevention and treatment. #CancerResearch #Microbiome #Immunotherapy #CancerPrevention

#ARTNetPublication New research in @CR_AACR reveals a promising strategy to overcome radioresistance in lung cancer. @BoyiGan, @ACKoongMDPhD, @StevenLin_MDPhD, @Dadi_Jiang, and colleagues identified DHODH as a key metabolic driver that protects tumor cells from ferroptosis while supporting DNA repair after radiation. Combining DHODH inhibition with radiotherapy and IFNγ/anti-PD-1 immunotherapy dramatically improved treatment response in preclinical models, highlighting a promising therapeutic strategy for lung cancer and potentially other solid tumors. Read the study: doi.org/10.1158/0008-5… #LungCancer #Radiotherapy #CancerResearch #Immunotherapy #Ferroptosis #Metabolism #AACR

Online now: Lactate binds and inhibits the innate immune sensor STING to promote tumor immune evasion dlvr.it/TTHSK0

In the latest issue! Excessive vascular integrity restricts anti-tumor immunity dlvr.it/TTJC8g

📢 Registration is now open for the NCI Workshop on Understanding Plasticity and its Role Across the Cancer Continuum! Join leading researchers to explore the molecular mechanisms of cell plasticity, its impact on cancer development, progression, and treatment response, and help shape future research directions. 💻 Virtual participation is open to the public 🗓️ Sept. 23–24, 2026 🔗 Register here: events.cancer.gov/dcb/plasticity…

To stay ahead of cancer, we need to understand how tumor cells adapt. This @theNCI study reveals how environmental stress can drive heritable changes in gene expression, offering new insights into one of cancer’s greatest challenges: drug resistance. go.nih.gov/iie4xBv

Introducing Tuesdays with Tony, a new weekly series from @NCIDirector Dr. Anthony 'Tony' Letai. Starting tomorrow, follow along on NCI’s LinkedIn and Instagram for Dr. Letai’s thoughts on NCI's work, the science we're tackling, and the questions we're trying to answer.

📢 Registration is now open for the @theNCI Workshop on "Understanding Plasticity and its Role Across the Cancer Continuum"! This workshop will bring together experts to explore the molecular mechanisms of cellular plasticity and its impact on cancer initiation, progression, therapeutic resistance, and treatment response. 🗓️ September 23–24, 2026 💻 In-person speakers & virtual public participation Register here: events.cancer.gov/dcb/plasticity… #CancerResearch #CancerBiology #CellPlasticity #TumorHeterogeneity #CancerPrevention #CancerInterception #NIH #NCI

Congratulations to @BoyiGan, @xingxing_zang, @StevenLin_MDPhD, and all co-authors on this outstanding study published in @CellCellPress! The team uncovers a powerful two-way connection between antitumor immunity and cuproptosis: CD8+ T cells enhance tumor sensitivity to copper-dependent cell death through the IFNγ–STAT1–IRF1–FDX1 axis, while cuproptotic tumor cells stimulate immune responses by acting as immunogenic cell death. Importantly, combining a cuproptosis inducer with anti-PD-L1 therapy helped overcome immunotherapy resistance across multiple preclinical models. A compelling example of how understanding cell death pathways can open new opportunities for cancer immunotherapy. sciencedirect.com/science/articl… #CancerResearch #Immunotherapy #Cuproptosis #CellPress #CancerImmunology

How do cancer-driving fusion proteins create their own vulnerabilities? A new #ARTNetPublication in @CR_AACR co-authored by Dr. Trever Bivona @BivonaLabUCSF shows that FET fusion oncoproteins impair ATM-mediated DNA damage repair, forcing tumors to rely on ATR signaling for survival. This collateral dependency may be exploited therapeutically with ATR inhibitors across multiple FET-rearranged cancers. pubmed.ncbi.nlm.nih.gov/41811428/ #CancerResearch #EwingSarcoma #DNARepair #PrecisionMedicine #ATRinhibitors